Shares Held by Insiders

Fully Diluted Shares Held by Insiders

Date

Name

Buy/Sell

$ Value

# Shares

Avg. Price

Title

Chief Executive Officer

Chief Technical Officer

Chief Scientific Officer

Chief Legal Officer

Chief Medical Officer

See Remarks

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a lymphocyte that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, that is in phase I for the treatment of various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc., a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment.

Datesorted ascending	Name	Buy/Sell	$ Value	# Shares	Avg. Price	Title
2024-03-27	Premium	bought	Premium	Premium	Premium	-
2024-03-27	Premium	bought	Premium	Premium	Premium	-
2024-03-27	Premium	bought	Premium	Premium	Premium	-
2024-03-04	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2024-03-01	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2024-03-01	Premium	sold	Premium	Premium	Premium	Chief Technical Officer
2024-03-01	Premium	back to issuer	Premium	Premium	Premium	Chief Executive Officer
2024-02-12	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-01-16	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2024-01-16	Premium	sold	Premium	Premium	Premium	Chief Executive Officer
2024-01-16	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2024-01-16	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2024-01-16	Premium	sold	Premium	Premium	Premium	Chief Technical Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	See Remarks
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Legal Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Executive Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Scientific Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Technical Officer
2024-01-04	Premium	acquired	Premium	Premium	Premium	Chief Medical Officer
2023-08-21	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-06-20	Premium	sold	Premium	Premium	Premium	Chief Medical Officer
2023-06-20	Premium	sold	Premium	Premium	Premium	Chief Legal Officer
2023-06-20	Premium	sold	Premium	Premium	Premium	Chief Technical Officer
2023-06-20	Premium	sold	Premium	Premium	Premium	Chief Scientific Officer
2023-06-20	Premium	sold	Premium	Premium	Premium	See Remarks

NKTX - Nkarta Inc Stock Price, Fair Value and News

Latest Insider Trading transactions for NKTX